MINERVA SURGICAL INC (UTRS) Forecast, Price Target & Analyst Ratings
NASDAQ:UTRS • US60343F2056
1.48 USD
-0.07 (-4.52%)
At close: Dec 28, 2023
1.53 USD
+0.05 (+3.38%)
After Hours: 12/28/2023, 8:06:43 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MINERVA SURGICAL INC (UTRS).
Forecast Snapshot
Consensus Price Target
$3.06
+ 106.76% Upside
Next Earnings Forecast
Release DateMar 19, 2024
PeriodQ4 / 2023
EPS Estimate-$0.55
Revenue Estimate14.178M
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.06
Upside
+ 106.76%
From current price of $1.48 to mean target of $3.06, Based on 7 analyst forecasts
Low
$3.03
Median
$3.06
High
$3.15
Price Target Revisions
1 Month
0.00%
3 Months
-85.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for UTRS. The average price target is 3.06 USD. This implies a price increase of 106.76% is expected in the next year compared to the current price of 1.48.
The average price target has been revised downward by 85% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
UTRS was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about UTRS.
In the previous month the buy percentage consensus was at a similar level.
UTRS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-05-03 | Piper Sandler | Maintains | Overweight |
| 2022-08-10 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2022-08-10 | Piper Sandler | Maintains | Overweight |
| 2022-05-12 | SVB Leerink | Maintains | Outperform |
| 2022-05-12 | Piper Sandler | Maintains | Overweight |
| 2022-03-09 | Piper Sandler | Maintains | Overweight |
| 2021-12-03 | SVB Leerink | Maintains | Outperform |
| 2021-11-16 | UBS | Initiate | Buy |
| 2021-11-16 | SVB Leerink | Initiate | Outperform |
| 2021-11-16 | JP Morgan | Initiate | Overweight |
| 2021-11-16 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 19, 2024
PeriodQ4 / 2023
EPS Estimate-$0.55
Revenue Estimate14.178M
Revenue Q2Q2.74%
EPS Q2Q86.23%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-3.99%
EPS (1 Month)
0.00%
EPS (3 Months)
-1,250.00%
Next Earnings Summary
UTRS is expected to report earnings on 3/19/2024. The consensus EPS estimate for the next earnings is -0.55 USD and the consensus revenue estimate is 14.18M USD.
The next earnings revenue estimate has been revised downward by 3.99% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 37.77M 45.21% | 52.1M 37.94% | 50.29M -3.47% | 52.836M 5.06% | 60.792M 15.06% | 69.87M 14.93% | |
| EBITDA YoY % growth | -8.31M 53.73% | -18.52M -122.86% | -20.09M -8.48% | -17.948M 10.66% | -17.752M 1.09% | -19.732M -11.15% | |
| EBIT YoY % growth | -15.39M 21.64% | -29.14M -89.34% | -30.9M -6.04% | -29.089M 5.86% | -26.678M 8.29% | -28.658M -7.42% | |
| Operating Margin | -40.75% | -55.93% | -61.44% | -55.06% | -43.88% | -41.02% | |
| EPS YoY % growth | N/A | N/A | -23.60 60.75% | -4.15 82.41% | -2.95 28.99% | -2.86 3.11% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.55 86.23% | -0.72 69.83% | -0.75 24.52% | -0.71 11.85% | -0.74 -35.19% | -0.71 2.39% | -0.73 2.84% | -0.69 3.29% | -0.73 2.60% |
| Revenue Q2Q % growth | 14.178M 2.74% | 14.484M 15.59% | 15.457M 15.44% | 14.79M 23.56% | 16.014M 12.95% | 16.626M 14.79% | 17.754M 14.86% | 17.034M 15.17% | 18.462M 15.29% |
| EBITDA Q2Q % growth | -2.726M -148.51% | -3.333M 57.26% | -4.474M -41.57% | -4.71M -2,843.98% | -5.235M -91.99% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.545M 12.43% | -6.296M 38.93% | -6.801M 11.21% | -6.528M -7.02% | -7.053M -55.18% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.40%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
10.85%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
11.17%
EBIT Next 5 Year
N/A
MINERVA SURGICAL INC / UTRS Forecast FAQ
What do analysts expect the price target to be for MINERVA SURGICAL INC (UTRS)?
7 analysts have analysed UTRS and the average price target is 3.06 USD. This implies a price increase of 106.76% is expected in the next year compared to the current price of 1.48.
What is the next earnings date for UTRS stock?
MINERVA SURGICAL INC (UTRS) will report earnings on 2024-03-19, after the market close.
What are the consensus estimates for UTRS stock next earnings?
The consensus EPS estimate for the next earnings of MINERVA SURGICAL INC (UTRS) is -0.55 USD and the consensus revenue estimate is 14.18M USD.
Can you provide the consensus rating for MINERVA SURGICAL INC stock?
The consensus rating for MINERVA SURGICAL INC (UTRS) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.